Related Experiment Videos
[Gliomatosis peritonei]
Abstract:
Gliomatosis peritonei, the miliary implants of mature glial tissues on the peritoneum or omentum, is a rare complication of solid ovarian teratoma. Our case is reported and 38 previously reported cases are reviewed. The grade of the primary tumors varied from grade 0 to grade 3. Only five cases were composed entirely of mature tissues. Five of the 39 patients died. Despite of varied therapy, the rest of the patients were alive from 3 months to 38 years later. Inspite of intraperitoneal implants, the prognosis in patients with these tumors is good, irrespective of the mode of therapy. On the basis of this study, we recommended a conservative therapy for the primary tumor and therapy for the implants is not required.
Insights
Gliomatosis peritonei, a rare complication of ovarian teratoma, involves glial tissue implants on the peritoneum. Despite varied treatments, prognosis is generally good, suggesting conservative management for primary tumors and no specific therapy for implants.
Area of Science:
- Gynecology
- Oncology
- Pathology
Background:
- Gliomatosis peritonei is a rare complication characterized by miliary implants of mature glial tissues on the peritoneum or omentum.
- It is typically associated with a solid ovarian teratoma.
- This condition presents a diagnostic and therapeutic challenge due to its rarity.
Observation:
- A case of gliomatosis peritonei is presented and reviewed alongside 38 previously reported cases.
- The primary ovarian tumors ranged in grade from 0 to 3.
- Only five cases (12.8%) consisted entirely of mature glial tissues.
Findings:
- Out of 39 patients, five (12.8%) died; the remaining 34 patients survived for 3 months to 38 years.
- Prognosis for patients with gliomatosis peritonei is generally good, irrespective of the primary tumor grade or therapy utilized.
- Intraperitoneal implants did not appear to negatively impact patient outcomes.
Implications:
- Conservative management of the primary ovarian teratoma is recommended.
- Specific therapy for gliomatosis peritonei implants is often not required, simplifying treatment protocols.
- Further research into the underlying mechanisms and optimal management strategies for this rare condition is warranted.